Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NYSE:ATNM NASDAQ:CRGX NASDAQ:HRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.04-0.5%$2.13$1.43▼$3.98$205.84M1.65109,799 shs110,093 shsATNMActinium Pharmaceuticals$1.78+2.3%$1.62$1.03▼$2.41$55.53M-0.53405,691 shs144,405 shsCRGXCARGO Therapeutics$4.47$4.45$3.00▼$25.45$216.17M0.31.73 million shsN/AHRTXHeron Therapeutics$1.35-2.9%$1.79$1.04▼$2.68$213.08M1.152.57 million shs1.14 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-0.49%-5.12%-6.42%+17.65%-35.03%ATNMActinium Pharmaceuticals+2.30%+2.30%+13.38%+15.58%-6.32%CRGXCARGO Therapeutics0.00%0.00%0.00%+5.42%-73.66%HRTXHeron Therapeutics-2.88%-3.57%-24.58%-28.57%-30.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune2.0507 of 5 stars3.51.00.00.03.10.80.6ATNMActinium Pharmaceuticals2.4194 of 5 stars3.55.00.00.01.10.00.6CRGXCARGO Therapeutics2.0504 of 5 stars2.90.00.00.02.01.71.3HRTXHeron Therapeutics4.081 of 5 stars3.21.00.04.22.83.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$12.00488.24% UpsideATNMActinium Pharmaceuticals 3.00Buy$4.50152.81% UpsideCRGXCARGO Therapeutics 1.86Reduce$15.40244.52% UpsideHRTXHeron Therapeutics 2.33Hold$4.50233.33% UpsideCurrent Analyst Ratings BreakdownLatest ATNM, CRGX, ACIU, and HRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025HRTXHeron TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell8/8/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.007/8/2025CRGXCARGO TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$3.70 ➝ $5.006/24/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/9/2025HRTXHeron TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$31.02M6.60N/AN/A$0.90 per share2.27ATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/ACRGXCARGO TherapeuticsN/AN/AN/AN/A$4.91 per shareN/AHRTXHeron Therapeutics$144.29M1.43N/AN/A($0.18) per share-7.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$57.83M-$0.58N/AN/AN/A-174.94%-49.35%-23.16%11/4/2025 (Estimated)ATNMActinium Pharmaceuticals-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/ACRGXCARGO Therapeutics-$167.50M-$4.64N/AN/AN/AN/A-43.21%-37.26%11/11/2025 (Estimated)HRTXHeron Therapeutics-$13.58M-$0.02N/AN/AN/A-0.62%N/A-0.40%11/11/2025 (Estimated)Latest ATNM, CRGX, ACIU, and HRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 million$37.20 million8/5/2025Q2 2025ACIUAC Immune-$0.20-$0.25-$0.05-$0.25$1.98 million$1.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AATNMActinium PharmaceuticalsN/AN/AN/AN/AN/ACRGXCARGO TherapeuticsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.331.33ATNMActinium PharmaceuticalsN/A10.2510.25CRGXCARGO TherapeuticsN/A12.3712.37HRTXHeron TherapeuticsN/A0.820.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%ATNMActinium Pharmaceuticals27.50%CRGXCARGO Therapeutics93.16%HRTXHeron Therapeutics80.01%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%ATNMActinium Pharmaceuticals6.00%CRGXCARGO Therapeutics2.92%HRTXHeron Therapeutics5.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million95.79 millionOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableCRGXCARGO Therapeutics11648.36 million46.95 millionN/AHRTXHeron Therapeutics300153.29 million144.31 millionOptionableATNM, CRGX, ACIU, and HRTX HeadlinesRecent News About These CompaniesHeron Therapeutics Signs New Headquarters LeaseAugust 28 at 5:30 PM | tipranks.comHeron Therapeutics: The View From 30,000 Feet Amid The Zynrelef LaunchAugust 25, 2025 | seekingalpha.comHeron Therapeutics (NASDAQ:HRTX) Rating Increased to Strong Sell at Zacks ResearchAugust 17, 2025 | marketbeat.comHeron Therapeutics adopts tax benefits preservation planAugust 16, 2025 | msn.comHeron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder ValueAugust 15, 2025 | prnewswire.comXTX Topco Ltd Sells 213,080 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)August 15, 2025 | marketbeat.comInsider Buying: Heron Therapeutics, Inc. (NASDAQ:HRTX) Major Shareholder Acquires 2,387,225 Shares of StockAugust 14, 2025 | marketbeat.comInsider Buying: Heron Therapeutics, Inc. (NASDAQ:HRTX) Director Purchases 1,766,546 Shares of StockAugust 14, 2025 | marketbeat.comInformed Momentum Co LLC Invests $768,000 in Heron Therapeutics, Inc. (NASDAQ:HRTX)August 14, 2025 | marketbeat.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Director Buys $2,649,819.00 in StockAugust 13, 2025 | insidertrades.comHeron Therapeutics Signs Agreement with PatheonAugust 12, 2025 | msn.comRubric capital buys Heron Therapeutics (HRTX) shares worth $3.5mAugust 12, 2025 | investing.comHeron Therapeutics Announces Strategic Financial InitiativesAugust 12, 2025 | theglobeandmail.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comHeron Therapeutics (NASDAQ:HRTX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPSAugust 11, 2025 | marketbeat.comHeron Therapeutics (NASDAQ:HRTX) Price Target Cut to $3.00 by Analysts at Needham & Company LLCAugust 10, 2025 | marketbeat.comWall Street Zen Downgrades Heron Therapeutics (NASDAQ:HRTX) to HoldAugust 10, 2025 | marketbeat.comHeron Therapeutics, Inc.: Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity ProfileAugust 8, 2025 | finanznachrichten.deHeron (HRTX) Q2 Acute Care Jumps 56%August 8, 2025 | aol.comAHeron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comHeron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesAugust 8, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATNM, CRGX, ACIU, and HRTX Company DescriptionsAC Immune NASDAQ:ACIU$2.04 -0.01 (-0.49%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.07 +0.03 (+1.47%) As of 08/29/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Actinium Pharmaceuticals NYSE:ATNM$1.78 +0.04 (+2.30%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.78 -0.01 (-0.28%) As of 08/29/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.CARGO Therapeutics NASDAQ:CRGX$4.47 0.00 (0.00%) As of 08/19/2025CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Heron Therapeutics NASDAQ:HRTX$1.35 -0.04 (-2.88%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.38 +0.02 (+1.85%) As of 08/29/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
